2017
DOI: 10.1158/1541-7786.mcr-16-0296
|View full text |Cite
|
Sign up to set email alerts
|

Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma

Abstract: Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with the 5-year survival rate less than 6%. Previous

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
42
0

Year Published

2017
2017
2023
2023

Publication Types

Select...
5
1

Relationship

3
3

Authors

Journals

citations
Cited by 47 publications
(47 citation statements)
references
References 45 publications
1
42
0
Order By: Relevance
“…The PDAC tissue microarrays (TMA) used in previous studies were obtained from 110 pancreatic cancer patients who underwent surgical resection at Fudan University Shanghai Cancer Center (FUSCC) . Prior patient consent and approval from the Institutional Research Ethics Committee were obtained.…”
Section: Methodsmentioning
confidence: 99%
See 2 more Smart Citations
“…The PDAC tissue microarrays (TMA) used in previous studies were obtained from 110 pancreatic cancer patients who underwent surgical resection at Fudan University Shanghai Cancer Center (FUSCC) . Prior patient consent and approval from the Institutional Research Ethics Committee were obtained.…”
Section: Methodsmentioning
confidence: 99%
“…IHC staining of paraffin‐embedded tissues with antibodies for MUC16, c‐Myc, FBW7 and CAV2 were performed and scored to determine the protein expression according to standard procedures as previously described . The following levels were based on the obtained positivity and intensity scores: 0, negative; 1, weakly positive; 2, moderately positive and 3, strongly positive.…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…Specifically, MUC16 is involved in inhibiting apoptosis and blunting the cellular response to genotoxic drugs [32]. As it plays an important role in the oncogenesis, MUC16 has garnered attention as a biomarker to monitor disease and predicting response to therapy [2,7,33].…”
Section: Pancreatic Cancermentioning
confidence: 99%
“…It is a well-established biomarker used to monitor the progression and recurrence of ovarian cancer. Furthermore, it is overexpressed in a range of human malignancies including ovarian, pancreatic, breast, cholangiocarcinoma, cervical, gastric and non-small cell lung cancer [1][2][3][4][5][6]. Mucins are a family of high molecular weight glycoproteins composed of oligosaccharides attached to a peptide core [7].…”
Section: Introductionmentioning
confidence: 99%